戻る Agenda
Session 10: Hot Topics in Oligonucleotide Therapeutics
Session Chair(s)
Arthur A. Levin, PhD
Senior Consultant
Levin BioScience, United States
As we learn more about RNA biology, its importance in the regulation of gene expression, and its role in disease processes, it is becoming clear there are many more ways to use oligonucleotides as therapeutic agents. With the identification of novel exploitable mechanism of RNA modulation, the range of diseases that can be targeted increases. This session will explore multiple novel ways to modulate RNA biology that may ultimately be used as a way to address disease processes and become the foundation for new therapeutic agents.
Learning Objective :
Speaker(s)
Session Co-Chair
Shwu-Luan Lee, PhD
FDA, United States
Pharmacologist, Office of New Drug, CDER
Antisense-Mediated Control of RNA Splicing to Treat Monogenic Diseases
Huw M. Nash, PhD
Stoke Therapeutics Inc., United States
Chief Executive Officer
A to I Editing and Neuronal Plasticity
Joshua Rosenthal, PhD
Marine Biological Laboratory, United States
Senior Scientist
A Site-Directed RNA Editing Strategy to Correct Genetic Mutations
Maria Montiel-Gonzalez, PhD
The Marine Biological Laboratory, University of Chicago, United States
Post Doctoral Fellow
Stereodefined LNA Phosphorothioates: A New Perspective in RNA Therapeutics
Troels Koch, PhD, MSc
Roche Innovation Center Copenhagen, Denmark
VP, Head of Research, RNA Therapeutics